Loading patent…
AssigneeCSL Behring GmbH
InventorsChristoph Kleinschnitz, Marc Nolte, Guido Stoll, Gerhard Dickneite, Stefan Schulte, Bernhard Nieswandt, Ingo Pragst
Estimating the term…
The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.
A C1-inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury, and spinal cord injury.
A C1-inhibitor for use in the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier in a subject wherein the disorder associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier is selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury, spinal cord injury, diabetes mellitus, multiple sclerosis, a bacterial infection of the CNS, preferably meningitis, viral infection infecting the brain, preferably HIV, and brain tumor, preferably metastasing brain tumor.
A C1-inhibitor for use in a method of preventing or reducing an increased permeability of the blood brain barrier or the blood spinal cord barrier in a subject wherein this increased permeability is associated with an disorder which is selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury, spinal cord injury, diabetes mellitus, multiple sclerosis, a bacterial infection of the CNS, preferably meningitis, viral infection infecting the brain, preferably HIV, and brain tumor, preferably metastasing brain tumor.
A plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury in a subject whereby the inhibitor is administered 30 minutes or more after start of reperfusion.
Dependencies are inferred from the claim text.